- Dubai Stock Selloff May Bring Buying Opportunity
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Dubai's Debt Woes Signal New Era for Creditors
- Longer Lines, Fuller Carts This Black Friday
- The World's Biggest Debtor Nations
- Five Tips for Buying a Foreclosed Home
- Shoppers Hit Black Friday Sales; Budgets Pared
- Slideshow: Fantasy Christmas Gifts 2009
- EA Sports Hopes to Pump Up Sales With Pop-Ups
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- 8 Retailers that Gain During the Holidays
- Farrell: What's Different On This Black Friday
- 10 Dividend Picks For Your Portfolio: Chief Investors
MOST SHARED
- 8 Retailers that Gain During the Holidays
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Get Paid Six Figures to Wear a T-Shirt?
- Finding the Holiday's Best Buys
- Dubai Spooks Investors But May Bring Buying Opportunity
- Banks Play Down Dubai Exposure, Investors Still Wary
- Some of Dubai World's Major Holdings Around Globe
- Banks With The Biggest Exposure to The UAE
- San Miguel Sells $1.36 Billion Stake to Ally
Text Size 
MUMBAI, Nov 7 (Reuters) - India's Dr Reddy's Laboratories has filed for marketing a generic version of Pfizer's cholesterol-lowering drug Lipitor in the U.S., the company said on Saturday. "We have filed an ANDA (abbreviated new drug filing) for atrovastatin and notified Pfizer accordingly," Dr Reddy's told Reuters in response to an email query. Earlier on Saturday, the Business Standard newspaper reported that Dr Reddy's had developed a generic version for Lipitor, and along with its U.S.
subsidiary, had informed Pfizer about applying to the U.S. Food and Drug Administration for marketing the drug. Lipitor is the world's largest selling drug, with global sales of $8.3 billion in the last nine months. So far, Ranbaxy is the only other Indian drugmaker to develop a generic for the drug, whose U.S. patent expires in 2010. Under a settlement with Pfizer, Ranbaxy has agreed to launch its generic by November 2011. (Reporting by Prashant Mehra;Editing by Sanjeev Miglani) ((prashant.mehra@thomsonreuters.com; +91 22 6636 9029; Reuters Messaging: prashant.mehra.reuters.com@reuters.net)) Keywords: DRREDDYS LIPITOR/ (If you have a query or comment on this story, send an email to newsfeedback.asia@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Print
Email
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- It may be the most unusual guide to business you'll read.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
- Some of the nation's top bartenders offer suggestions on what to serve at holiday celebrations this year.
Data is a real-time snapshot *Data is delayed at least 15 minutes